<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>483-SUBSTRATES-AT-RISK-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTRATES AT RISK OF CYP3A4" code="L01N01" /></DRUG1>
<DRUG2>
<DRUG name="CRIZOTINIB" rxcui="1148495">
<ATC code="L01XE16" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the toxicity of these molecules due to decrease of their metabolism and/or increase of their bioavailability by the crizotinib</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>483-SUBSTRATES-AT-RISK-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTRATES AT RISK OF CYP3A4" code="L01N01" /></DRUG1>
<DRUG2>
<DRUG name="IDELALISIB" rxcui="1544460">
<ATC code="L01XX47" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the substrate due to decrease of its hepatic metabolism by the idealisib</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>483-SUBSTRATES-AT-RISK-OF-CYP3A4.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTRATES AT RISK OF CYP3A4" code="L01N01" /></DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the undesirable effects particular to each substrate, with frequently severe consequences</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
</INTERACTIONS>
